Copenhagen Pharma Consulting ApS: Financial statements 2022
CVR: 41537388
Source: annual report 2022, Danish Business Authority
01/01/2022 – 31/12/2022
Copenhagen Pharma Consulting ApS (CVR 41537388) has filed annual accounts for 2022. In 2022, the company reported a gross profit of DKK 1,304,771 and a net result of DKK -37,796. Equity in the 2022 report amounted to DKK 906,160. The solvency ratio was 72.7%. The company had 2 employees in the financial year.
- Gross Profit
- DKK 1,304,771
- Profit/Loss
- DKK -37,796
- Equity
- DKK 906,160
- Total Assets
- DKK 1,245,586
- Employees
- 2
Official annual report
Keep an eye on Copenhagen Pharma Consulting ApS
Get notified instantly about new financial statements, ownership changes, management changes and status changes.
Set up monitoringEvents in 2022
Copenhagen Pharma Consulting ApS has published its interim report for the period July 23, 2020 to December 31, 2021.
As of January 1, 2022, Obi1 Holding ApS is registered as an owner of Copenhagen Pharma Consulting ApS with an ownership share of 100%.
About Copenhagen Pharma Consulting ApS
Copenhagen Pharma Consulting ApS is a Danish company of the type Anpartsselskab based in Vanløse, founded in 2020. The company is registered under the industry Andre liberale, videnskabelige og tekniske tjenesteydelser i.a.n.. The management consists of Lars Holten-Andersen. The company is owned by Obi1 Holding ApS. The company has 2 employees (2026). In 2025, the company reported a gross profit of DKK 3,364,006 and a net result of DKK 419,568 compared with DKK 558,252 the year before. Equity in the 2025 report amounted to DKK 601,867.
